carbamates has been researched along with Alloxan Diabetes in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "Repaglinide is a novel insulin secretagogue being developed for the management of type 2 (non-insulin-dependent) diabetes mellitus." | 2.40 | Repaglinide. ( Balfour, JA; Faulds, D, 1998) |
| "Repaglinide (RPG) is an oral insulin secretagogue used in the treatment of diabetes." | 1.72 | Antidiabetic and neuroprotective effects of a novel repaglinide analog. ( Abdollahi, M; Asgarian, S; Baeeri, M; Dehpour, AR; Emamgholipour, Z; Firoozpour, L; Foroumadi, A; Foroumadi, R; Gholami, M; Goli, F; Keykhaei, M, 2022) |
| "Repaglinide and metformin were complexed with amberlite resin; later resin complexed drug was encapsulated in Ethylcellulose floating microspheres." | 1.62 | Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes. ( Jain, AK; Jain, SK; Mishra, K; Sahu, P, 2021) |
| "Experimental diabetes mellitus was produced by a single intraperitoneal injection of STZ (55mg/kg b." | 1.43 | Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats. ( Berredjem, H; Berredjem, M; Bouzerna, N; Cheloufi, H; Réggami, Y, 2016) |
| "Ritonavir is an antiretroviral drug to treat HIV AIDS and inhibits cytochrome P450 3A4." | 1.43 | Altered pharmacokinetics and pharmacodynamics of repaglinide by ritonavir in rats with healthy, diabetic and impaired hepatic function. ( Goud, T; Maddi, S; Nayakanti, D; Thatipamula, RP, 2016) |
| "Repaglinide (RPG) is a fast-acting prandial glucose regulator." | 1.43 | Nanoemulsion: for improved oral delivery of repaglinide. ( Akhtar, J; Aqil, M; Fareed, S; Khalid, M; Siddiqui, HH, 2016) |
| " Designing a controlled release dosage form of the drug is required to maintain its therapeutic blood level and to eliminate its adverse effects, particularly the hypoglycaemia." | 1.40 | Preparation and evaluation of a controlled drug release of repaglinide through matrix pellets: in vitro and in vivo studies. ( Minaiyan, M; Pendar, Y; Tabbakhian, M; Tavakoli, N, 2014) |
| "Repaglinide is a short-acting, oral, insulin secretagogue that is used in the treatment of type 2 diabetes mellitus." | 1.38 | Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits. ( Reddy, PJ; Sekhar, MC, 2012) |
| "In pioglitazone-treated animals, AA and TAS increased above control values while GSH and PCG were normalized." | 1.38 | Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide. ( Gumieniczek, A; Owczarek, B; Pawlikowska, B, 2012) |
| " Solid lipid nanoparticles were prepared by modified solvent injection method for oral delivery to improve the bioavailability of RG, an antidiabetic drug." | 1.37 | Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. ( Jain, A; Rawat, MK; Singh, S, 2011) |
| "The purpose of this work was to develop prolonged release binary lipid matrix-based solid lipid nanoparticles (SLN) of repaglinide (RG) for oral intestinal delivery and to improve the bioavailability of RG." | 1.37 | In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. ( Jain, A; Rawat, MK; Singh, S, 2011) |
| "Methiocarb is an N-methylcarbamate insecticide used worldwide in agriculture and health programs." | 1.36 | Effects of methiocarb on lipid peroxidation and glutathione level in rat tissues. ( Alpertunga, B; Ozden, S, 2010) |
| "Diabetes caused significant hyperalgesia during these tests." | 1.35 | URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats. ( Hasanein, P; Keshavarz, M; Parviz, M; Roohbakhsh, A, 2009) |
| "Repaglinide (RPG) is an oral hypoglycemic agent with excellent bioavailability (90-98%) and a short plasma half-life (2-6 h)." | 1.35 | Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ( Jain, S; Saraf, S, 2009) |
| "Repaglinide is a new oral antidiabetic agent with a possible antioxidant activity." | 1.33 | Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. ( Bojarska-Junak, A; Gumieniczek, A; Hopkała, H; Roliński, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (14.63) | 18.7374 |
| 1990's | 4 (9.76) | 18.2507 |
| 2000's | 10 (24.39) | 29.6817 |
| 2010's | 19 (46.34) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Foroumadi, R | 1 |
| Baeeri, M | 1 |
| Asgarian, S | 1 |
| Emamgholipour, Z | 1 |
| Goli, F | 1 |
| Firoozpour, L | 1 |
| Keykhaei, M | 1 |
| Gholami, M | 1 |
| Dehpour, AR | 1 |
| Abdollahi, M | 1 |
| Foroumadi, A | 1 |
| Jain, AK | 1 |
| Sahu, P | 1 |
| Mishra, K | 1 |
| Jain, SK | 1 |
| Nicolas, C | 1 |
| Jaisson, S | 1 |
| Gorisse, L | 1 |
| Tessier, FJ | 1 |
| Niquet-Léridon, C | 1 |
| Jacolot, P | 1 |
| Pietrement, C | 1 |
| Gillery, P | 1 |
| de Morais, H | 1 |
| Chaves, YC | 1 |
| Waltrick, APF | 1 |
| Jesus, CHA | 1 |
| Genaro, K | 1 |
| Crippa, JA | 1 |
| da Cunha, JM | 1 |
| Zanoveli, JM | 1 |
| Tavakoli, N | 1 |
| Minaiyan, M | 1 |
| Tabbakhian, M | 1 |
| Pendar, Y | 1 |
| Elmowafy, E | 2 |
| Osman, R | 2 |
| El-Shamy, Ael-H | 1 |
| Awad, GA | 2 |
| Wang, Y | 1 |
| Tar, MT | 1 |
| Fu, S | 1 |
| Melman, A | 1 |
| Davies, KP | 1 |
| El-Shamy, AH | 1 |
| Li, F | 1 |
| Xu, D | 1 |
| Shu, N | 1 |
| Zhong, Z | 1 |
| Zhang, M | 1 |
| Liu, C | 1 |
| Ling, Z | 1 |
| Liu, L | 1 |
| Liu, X | 1 |
| Chukwunonso Obi, B | 1 |
| Chinwuba Okoye, T | 1 |
| Okpashi, VE | 1 |
| Nonye Igwe, C | 1 |
| Olisah Alumanah, E | 1 |
| Varshosaz, J | 1 |
| Minayian, M | 1 |
| Ahmadi, M | 1 |
| Ghassami, E | 1 |
| Réggami, Y | 1 |
| Berredjem, H | 1 |
| Cheloufi, H | 1 |
| Berredjem, M | 1 |
| Bouzerna, N | 1 |
| Goud, T | 1 |
| Maddi, S | 1 |
| Nayakanti, D | 1 |
| Thatipamula, RP | 1 |
| Akhtar, J | 1 |
| Siddiqui, HH | 1 |
| Fareed, S | 1 |
| Khalid, M | 1 |
| Aqil, M | 1 |
| Marcus, DJ | 1 |
| Zee, ML | 1 |
| Davis, BJ | 1 |
| Haskins, CP | 1 |
| Andrews, MJ | 1 |
| Amin, R | 1 |
| Henderson-Redmond, AN | 1 |
| Mackie, K | 1 |
| Czyzyk, TA | 1 |
| Morgan, DJ | 1 |
| Hasanein, P | 1 |
| Parviz, M | 1 |
| Keshavarz, M | 1 |
| Roohbakhsh, A | 1 |
| Ozden, S | 1 |
| Alpertunga, B | 1 |
| Gumieniczek, A | 6 |
| Krzywdzińska, M | 1 |
| Nowak, M | 1 |
| Jain, S | 1 |
| Saraf, S | 1 |
| Rawat, MK | 2 |
| Jain, A | 2 |
| Singh, S | 2 |
| Date, AA | 1 |
| Vador, N | 1 |
| Jagtap, A | 1 |
| Nagarsenker, MS | 1 |
| Sekhar, MC | 1 |
| Reddy, PJ | 1 |
| Owczarek, B | 1 |
| Pawlikowska, B | 1 |
| Field, MJ | 2 |
| Gonzalez, MI | 1 |
| Tallarida, RJ | 1 |
| Singh, L | 2 |
| el-Batran, SA | 1 |
| el-Shenawy, SM | 1 |
| Nofal, SM | 1 |
| Abdel-Salam, OM | 1 |
| Arbid, MS | 1 |
| Hopkała, H | 1 |
| Roliński, J | 1 |
| Bojarska-Junak, A | 1 |
| Schmidt, RE | 1 |
| Green, KG | 1 |
| Feng, D | 1 |
| Dorsey, DA | 1 |
| Parvin, CA | 1 |
| Lee, JM | 1 |
| Xiao, Q | 1 |
| Brines, M | 1 |
| Jordá, A | 1 |
| Cabo, J | 1 |
| Grisolia, S | 1 |
| Ladrière, L | 2 |
| Malaisse-Lagae, F | 2 |
| Fuhlendorff, J | 1 |
| Malaisse, WJ | 2 |
| McCleary, S | 1 |
| Boden, P | 1 |
| Suman-Chauhan, N | 1 |
| Hughes, J | 1 |
| Laghmich, A | 1 |
| Balfour, JA | 1 |
| Faulds, D | 1 |
| Camerini-Davalos, RA | 1 |
| Reddi, AS | 1 |
| Ehrenreich, TH | 1 |
| Strugatz, LH | 1 |
| Oppermann, W | 1 |
| Schein, PS | 1 |
| Alberti, KG | 1 |
| Williamson, DH | 1 |
| Herrman, JL | 1 |
| Nordlie, RC | 1 |
| Mackerer, CR | 1 |
| Paquet, RJ | 1 |
| Mehlman, MA | 1 |
| Tobin, RB | 1 |
| Blickens, DA | 1 |
| Riggi, SJ | 1 |
1 review available for carbamates and Alloxan Diabetes
| Article | Year |
|---|---|
Repaglinide.
Topics: Animals; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glyburide; Humans; | 1998 |
40 other studies available for carbamates and Alloxan Diabetes
| Article | Year |
|---|---|
Antidiabetic and neuroprotective effects of a novel repaglinide analog.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Benzoic Acid; Biomarkers; Blood Glucose; Carbamates; | 2022 |
Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes.
Topics: Animals; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Metformin; Mice; Mi | 2021 |
Carbamylation is a competitor of glycation for protein modification in vivo.
Topics: Albumins; Animals; Blood Glucose; Blood Proteins; Carbamates; Cyanates; Diabetes Mellitus, Experimen | 2018 |
Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats.
Topics: Animals; Antidepressive Agents; Benzamides; Cannabidiol; Carbamates; Depression; Diabetes Mellitus, | 2018 |
Preparation and evaluation of a controlled drug release of repaglinide through matrix pellets: in vitro and in vivo studies.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Cellulose; Diabetes Mellitus, Experimental | 2014 |
Nasal polysaccharides-glucose regulator microparticles: optimization, tolerability and antidiabetic activity in rats.
Topics: Administration, Intranasal; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Dru | 2014 |
Diabetes attenuates urothelial modulation of detrusor contractility and spontaneous activity.
Topics: Animals; Anthracenes; Carbachol; Carbamates; Cholinergic Agonists; Diabetes Mellitus, Experimental; | 2014 |
Nanocomplexes of an insulinotropic drug: optimization, microparticle formation, and antidiabetic activity in rats.
Topics: Administration, Intranasal; Animals; Blood Glucose; Carbamates; Cell Line; Cell Survival; Chemistry, | 2014 |
Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution.
Topics: Administration, Intravenous; Administration, Oral; Animals; Body Fluids; Carbamates; Cell Separation | 2015 |
Comparative Study of the Antioxidant Effects of Metformin, Glibenclamide, and Repaglinide in Alloxan-Induced Diabetic Rats.
Topics: Alloxan; Animals; Antioxidants; Biomarkers; Blood Glucose; Carbamates; Catalase; Diabetes Complicati | 2016 |
Enhancement of solubility and antidiabetic effects of Repaglinide using spray drying technique in STZ-induced diabetic rats.
Topics: Animals; Calorimetry, Differential Scanning; Carbamates; Diabetes Mellitus, Experimental; Hypoglycem | 2017 |
Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats.
Topics: Animals; Atherosclerosis; Bilirubin; Blood Glucose; Body Weight; Carbamates; Creatinine; Diabetes Me | 2016 |
Altered pharmacokinetics and pharmacodynamics of repaglinide by ritonavir in rats with healthy, diabetic and impaired hepatic function.
Topics: Alloxan; Animals; Blood Glucose; Carbamates; Carbon Tetrachloride; Chemical and Drug Induced Liver I | 2016 |
Nanoemulsion: for improved oral delivery of repaglinide.
Topics: Administration, Oral; Animals; Biopharmaceutics; Carbamates; Diabetes Mellitus, Experimental; Drug S | 2016 |
Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic.
Topics: Amino Acid Substitution; Animals; Body Weight; Carbamates; Diabetes Mellitus, Experimental; Dose-Res | 2016 |
URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats.
Topics: Amidohydrolases; Animals; Benzamides; Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; C | 2009 |
Effects of methiocarb on lipid peroxidation and glutathione level in rat tissues.
Topics: Animals; Antioxidants; Carbamates; Diabetes Mellitus, Experimental; Free Radical Scavengers; Glutath | 2010 |
Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Catalase; Diabetes Mellitus, Experimental; | 2009 |
Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Chemistry, Pharmaceutical; Delayed-Action | 2009 |
Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Calorimetry, Differential Sca | 2011 |
In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Topics: Animals; Biological Availability; Blood Glucose; Carbamates; Cell Survival; Cells, Cultured; Chromat | 2011 |
Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
Topics: Administration, Oral; Animals; Blood Glucose; Calorimetry, Differential Scanning; Carbamates; Diabet | 2011 |
Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits.
Topics: Animals; Atorvastatin; Blood Glucose; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme In | 2012 |
Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide.
Topics: Animals; Antioxidants; Aqueous Humor; Carbamates; Diabetes Mellitus, Experimental; Glutathione Perox | 2012 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Ex | 2004 |
Effects of repaglinide on oxidative stress in tissues of diabetic rabbits.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Experiment | 2005 |
Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide.
Topics: Animals; Blood Glucose; Body Weight; Carbamates; Catalase; Diabetes Mellitus, Experimental; Hypoglyc | 2005 |
Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Blood Glucose; Carbamates; Diabetes | 2005 |
Modification of cardiac oxidative stress in alloxan-induced diabetic rabbits with repaglinide treatment.
Topics: Alloxan; Animals; Antioxidants; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Insulin; | 2005 |
Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.
Topics: Animals; Carbamates; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Erythr | 2008 |
Changes in the levels of urea cycle enzymes and in metabolites thereof in diabetes.
Topics: Acetyltransferases; Amidohydrolases; Amino-Acid N-Acetyltransferase; Animals; Argininosuccinate Lyas | 1981 |
Effect of antidiabetic agents on the increase in glycemia and insulinemia caused by refeeding in hereditarily diabetic rats.
Topics: Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Food; Glyburide; Hypoglycemic A | 1997 |
Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
Topics: Animals; Benzofurans; Carbamates; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Electrophy | 1998 |
Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Diabetes | 1998 |
Diabetic glomerulosclerosis in KK mice and its prevention by glyburide and pyridinolcarbamate.
Topics: Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose | 1979 |
Effects of streptozotocin on carbohydrate and lipid metabolism in the rat.
Topics: Acetoacetates; Animals; Antibiotics, Antineoplastic; Blood Glucose; Carbamates; Diabetes Mellitus; D | 1971 |
Hepatic carbamyl phosphate: glucose phosphotransferase. Distribution, comparative kinetics, and responses to alloxan- or mannoheptulose-induced diabetes.
Topics: Amphibians; Animals; Astacoidea; Birds; Carbamates; Catalysis; Cats; Cattle; Diabetes Mellitus; Diab | 1972 |
Oxidation and phosphorylation in live mitochondria from alloxan and steptozotocin diabetic rats.
Topics: Animals; Carbamates; Diabetes Mellitus; Diabetes Mellitus, Experimental; Glucosamine; Glutarates; Ma | 1971 |
Carbohydrate metabolism in normal and hyperglycemic animals treated with 1-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride and phenformin.
Topics: Animals; Blood Glucose; Carbamates; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, E | 1971 |